TB vaccine development: monitoring international patent filings to anticipate access challenges
Maps international patent filings for two late-stage TB vaccine candidates, MTBVAC and M72/AS01E, as well as the QS-21 adjuvant used in M72/AS01E
Indonesia
IAVI
1. Understand likely use cases, delivery strategies, target populations, and drivers of preference and adoption; 2. Project demand; 3. Evaluate potential willingness to pay and budget impact; 4. Explore innovative financing mechanisms;
A model for the epidemiological impact of tuberculosis policy options
Develops a new TB transmission model to help decision-makers comapre the epidemiological impact of different TB interventions and allocate resources. The model incorporates diagnosis, treatment, drug resistance, HIV status, age, and vaccination status, and was calibrated using data from 29 high burden countries. It demonstrates the potential impact of comprehensive TB interventions in Indonesia and Nigeria, including the possible use of a post-exposure TB vaccine
How can new TB vaccines be effectively introduced in Indonesia?
Explores how Indonesia could prepare for and successfully introduce a new adult TB vaccine. It brought together 28 stakeholders form TB, immunisation and international organisations to examine potential target popualtions, delievery strategies, financing , vaccine accpetability, helath system readinessfor vaccine introduction
The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries
This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002
Supporting countries with prioritization of new vaccine introductions (NVI) and portfolio optimization
Support countries with using multi-criteria decision analysis (MCDA) for prioritization of new vaccine introductions (NVI) (including new TB vaccines) and portfolio optimization, embedded in the NIS development process. The project's key questions are: 1. How can we best support countries with NVI including new TB vaccine prioritization regarding access to evidence, tools, technical support? 2. What criteria do countries use when prioritizing NVIs? 3. How to best align NVI prioritization with the NIS development process.
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
Part of Change 2.0
Actionable market intelligence, including vaccine demand forecast/scenarios, generated to strategically guide manufacturers and partners in their planning for introduction in high burden countries. The objectives include: 1. Strategic assessment of appropriate market-shaping interventions, 2.Stakeholder and decision process mapping , 3.Demand dynamics understanding and realistic market forecast development, 4. Commercialization strategy support for lead candidate(s).
Creating evidence to support tuberculosis (TB) national and global decision-makers in reducing the global burden of TB
In strong collaboration, we (India, South Africa, Brazil, Indonesia, UK) will create evidence to strengthen capacity and sustainably support high tuberculosis (TB) burden countries (HBC) and global decision-makers in reducing the global burden of TB, by using modelling tools to address key questions on drug-resistant (DR-)TB, new TB vaccines and other interventions, and extend and apply a state-of-the-art TB model, to estimate the relative health, cost-effectiveness, and budget impact, of new and existing interventions, as well as their optimal combination.